Florian Langer
Prof. Dr. med.
Florian Langer
  • Medical Specialist in Internal Medicine
  • Facharzt für Hämatologie - Internistische Onkologie
  • Coagulation Tests
  • Working area 1
Languages
German (Mother tongue)
English

Areas of expertise

Awards

Memberships

Publications

Zurück
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
Vor

The impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort study
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2018;38(3):150-157.

Überbrückende Antikoagulation bei Patienten unter Vitamin-K-Antagonisten: Eine Bestandsaufnahme
Schellong S, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R
INTERNIST. 2018;59(7):744-752.

Überbrückende Antikoagulation bei Patienten unter Vitamin-K-Antagonisten: Eine Bestandsaufnahme
Schellong S, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R
ANAESTHESIST. 2018;67(8):599-606.

Management of cancer-associated venous thromboembolism - a case-based practical approach
Voigtlaender M, Langer F
VASA. 2018;47(2):77-89.

Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis
Bauersachs R, Gerlach H, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E
J VASC SURG. 2017;5(4):553-560.e1.

Myeloperoxidase Is a Negative Regulator of Phospholipid-Dependent Coagulation
Beckmann L, Dicke C, Spath B, Lehr C, Sievers B, Klinke A, Baldus S, Rudolph V, Langer F
THROMB HAEMOSTASIS. 2017;117(12):2300-2311.

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)
Miesbach W, Reitter-Pfoertner S, Klamroth R, Langer F, Wolf H, Tiede A, Siegmund B, Scholz U, Müller P, Eichler H, Pabinger I
HAEMOPHILIA. 2017;23(5):721-727.

Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking
Rothmeier A, Marchese P, Langer F, Kamikubo Y, Schaffner F, Cantor J, Ginsberg M, Ruggeri Z, Ruf W
ARTERIOSCL THROM VAS. 2017;37(7):1323-1331.

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development
Subramaniam S, Jurk K, Hobohm L, Jäckel S, Saffarzadeh M, Schwierczek K, Wenzel P, Langer F, Reinhardt C, Ruf W
BLOOD. 2017;129(16):2291-2302.

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2017;37(4):241-255.

Tumorassoziierte venöse Thromboembolien
Voigtländer M, Langer F
Vasomed. 2017;29(3):127-134.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48]
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;146:135.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;141:39-48.

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias
Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F
ANN HEMATOL. 2016;95(6):945-57.

The impact of social factors on outcomes in patients with bleeding disorders
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(1):46-53.

The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies
Nickel K, Labberton L, Long A, Langer F, Fuchs T, Stavrou E, Butler L, Renné T
THROMB RES. 2016;141 Suppl 2:S4-7.

Expression and release of platelet protein disulphide isomerase in patients with haemophilia A
Voigtländer M, Holstein K, Spath B, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(6):e537-e544.

S2k-Leitlinie Qualitätsanforderungen in der gastrointestinalen Endoskopie, AWMF Register Nr. 021-022. Erstauflage 2015
Denzer U, Beilenhoff U, Eickhoff A, Faiss S, Hüttl P, In der Smitten S, Jakobs R, Jenssen C, Keuchel M, Langer F, Lerch M, Lynen Jansen P, May A, Menningen R, Moog G, Rösch T, Rosien U, Vowinkel T, Wehrmann T, Weickert U
Z GASTROENTEROL. 2015;53(12):E1-227.

Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study
Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, Francis J, Bokemeyer C, Langer F
Exp Hematol Oncol. 2015;4:22.

Atypical venous thromboses in myeloproliferative neoplasias
Dicke C, Frölich A, Holstein K, Bokemeyer C, Langer F
PHLEBOLOGIE. 2015;44(6):324–329.

Pathophysiology of Trousseau's syndrome
Dicke C, Langer F
HAMOSTASEOLOGIE. 2015;35(1):52-9.

Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy
Jacobsen C, Oechsle K, Hauschild J, Steinemann G, Spath B, Bokemeyer C, Ruf W, Honecker F, Langer F
THROMB RES. 2015;136(3):673-81.

Hämostaseologische Aspekte in der Onkologie
Langer F
HAMOSTASEOLOGIE. 2015;35(2):152-64; quiz 165.

The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis
Nickel K, Ronquist G, Langer F, Labberton L, Fuchs T, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou E, Ronquist G, Renné T
BLOOD. 2015;126(11):1379-89.

Thrombin generation in a patient with an acquired high-titre factor V inhibitor
Schmidt D, Steinhagen F, Schnabel C, Spath B, Holstein K, Fiedler W, Bokemeyer C, Renné T, Langer F
BLOOD COAGUL FIBRIN. 2015;26(1):81-87.

Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia
Voigtländer M, Conradi L, Hinsch A, Langer F
Thorac Cardiovasc Surg Rep. 2015;4(1):40-43.

Clinical Evidence that Coagulation Activation Drives Cancer Progression - a Report of 2 Cases
Voigtländer M, Holstein K, Leuenroth S, Mudter J, Bokemeyer C, Langer F
ONCOL RES TREAT. 2015;38(9):449-52.

Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
Dicke C, Holstein K, Schneppenheim S, Dittmer R, Schneppenheim R, Bokemeyer C, Iking-Konert C, Budde U, Langer F
Exp Hematol Oncol. 2014;3:21.

Relationship between haemophilia and social status
Holstein K, Eifrig B, Langer F
THROMB RES. 2014.

Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor
Holstein K, Schneppenheim R, Schrum J, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2014;34 (4A):5-8.

Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion
Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White J, Budde U, Bokemeyer C, Schneppenheim R
THROMB HAEMOSTASIS. 2014;111(4):777-779.

Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation
Langer F, Ruf W
THROMB HAEMOSTASIS. 2014;111(4):590-7.

Bridging: Perioperatives Vorgehen bei dauerhafter oraler Antikoagulation oder Plättchenfunktionshemmung
Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe R
DEUT MED WOCHENSCHR. 2014;139(24):1301-6.

Seltene Gerinnungsstörung oder ein Fall für den Psychiater
Zinser M, Holstein K, Langer F, Voigt P, Holzhüter J
Hamb Ärztebl. 2014;2014(11):30-31.

Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses
Amirkhosravi A, Bigsby G, Desai H, Rivera-Amaya M, Coll E, Robles-Carrillo L, Faust P, Waters A, Meyer T, Reyes E, Langer F, Francis J
BLOOD COAGUL FIBRIN. 2013;24(5):510-7.

Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy
Honecker F, Koychev D, Lühmann A, Langer F, Dieckmann K, Bokemeyer C, Oechsle K
ONKOLOGIE. 2013;36(11):663-8.

Relevant bleeding diathesis due to acquired factor XIII deficiency
Janning M, Holstein K, Spath B, Schnabel C, Bannas P, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2013;33 Suppl 1:S50-4.

Perioperative thromboprophylaxis
Langer F
Viszeralmedizin. 2013;29(5):297-302.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
Holstein K, Marx G, Lentz B, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2012;32 Suppl 1:48-51.

Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor.
Langer F, Bokemeyer C
HAMOSTASEOLOGIE. 2012;32(2):95-104.

Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B, Hansen A, Bokemeyer C, Langer F
PLATELETS. 2012;23(1):60-68.

Akute Blutungen ohne Trauma - Gerinnung checken mit System
Langer F, Holstein K, Bokemeyer C
Der Allgemeinarzt. 2011;33(15):37-40.

[Venous thrombembolism in tumour patients].
Pabinger I, Alt-Epping B, Demarmels Biasutti F, Langer F, Wörmann B, Riess H
HAMOSTASEOLOGIE. 2011;31(4):281-282.

Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.
Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Dávila M, Langer F, Amaya M, Garber E, Francis J, Hsu Y, Amirkhosravi A
J IMMUNOL. 2010;185(3):1577-1583.

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
Haubold K, Rink M, Spath B, Friedrich M, Chun F, Marx G, Amirkhosravi A, Francis J, Bokemeyer C, Eifrig B, Langer F
THROMB HAEMOSTASIS. 2009;101(6):1147-1155.

Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis.
Ingersoll S, Langer F, Walker J, Meyer T, Robson T, Amaya M, Desai H, Francis J, Amirkhosravi A
CLIN EXP METASTAS. 2009;26(7):829-837.

Thromboembolische Komplikationen - Prophylaxe und Therapie im Fokus
Langer F, Holstein K, Eifrig B, Bokemeyer C
ONKOLOGE. 2009;15:150-156.

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.
Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis J, Amirkhosravi A
J THROMB HAEMOST. 2009;7(1):171-181.

A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin.
Gerdsen F, Luxembourg B, Langer F, Bauersachs R, Lindhoff-Last E
BLOOD COAGUL FIBRIN. 2008;19(6):477-481.

[Haemostatic aspects in clinical oncology]
Langer F, Holstein K, Eifrig B, Bokemeyer C
HAMOSTASEOLOGIE. 2008;28(5):472-480.

Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, Brümmendorf T, Dierlamm J, Bokemeyer C, Eifrig B
ANN HEMATOL. 2008;87(6):451-457.

Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F, Chun F, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis J
THROMB HAEMOSTASIS. 2007;97(3):464-470.

Letzte Aktualisierung aus dem FIS: 18.10.2019 - 05:27 Uhr